Xilio Therapeutics Plans Private Placement, Job Cuts
By Colin Kellaher
Xilio Therapeutics, which has struck a potentially lucrative licensing agreement with Gilead Sciences, on Thursday said it is raising $11.3 million in a private-placement financing and cutting staff in a repositioning.
The Waltham, Mass., clinical-stage biotechnology company said it agreed to sell nearly 17.6 million shares and prefunded warrants to certain existing accredited investors, including Bain Capital Life Sciences and Rock Springs Capital, at 64 cents apiece, in line with Wednesday's closing price.
The new funds are in addition to the $13.5 million that Gilead is investing in Xilio as part of the licensing agreement. Xilio said Gilead is making its investment at $1.97 a share, more than triple Wednesday's closing price.
Xilio also said it plans to reprioritize its resources and portfolio, resulting in the elimination of 15 jobs, or 21% of its staff.
The company said it will now focus on rapidly advancing clinical development for its XTX301 and XTX101 programs while ending further investment in XTX202 as a monotherapy.
Xilio said it expects the private placement and the Gilead investment, along with its repositioning, will extend its cash runway into the second quarter of 2025.
Trading in shares of Xilio was halted premarket on Thursday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 28, 2024 07:47 ET (11:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth